Abbott’s Plan To Revive Levosimendan NDA Must Survive Mortality Trial Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott appears unlikely to meet its year-end NDA filing target for levosimendan after the failure of the acute heart failure drug to meet its primary endpoint in a large mortality trial